Folliculotropic mycosis fungoides responding to bexarotene gel
Walling, H.W.; Swick, B.L.; Gerami, P.; Scupham, R.K.
Journal of Drugs in Dermatology Jdd 7(2): 169-171
2008
ISSN/ISBN: 1545-9616 PMID: 18335654 Document Number: 12687
Folliculotropic mycosis fungoides (FMF) is an uncommon and potentially aggressive form of cutaneous T cell lymphoma (CTCL). Phototherapy, radiotherapy, and systemic chemotherapy are the most commonly employed treatment options, but may have limited success and common adverse reactions. Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FME The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.
Document emailed within 1 workday
